Pre-earnings brief
Reports
Tue, Nov 3, 2026
Est. EPS
—
Est. revenue
—
Implied move
±12.6%
EPS beat rate
38%
Cryoport, Inc. is a healthcare company specializing in life sciences tools and services, particularly in the area of temperature-controlled logistics for biopharmaceutical products. With a market cap of $1 billion, it plays a crucial role in the supply chain for therapies that require precise temperature management, which is increasingly important as the biotech industry grows.
Last quarter
In the last quarter, Cryoport reported an EPS of -$0.20, matching analyst expectations but showing no revenue figures. The stock reacted negatively, dropping 3.54% the following day.
EPS beat streak
0Q
EPS beat rate
38%
Avg EPS surprise
+141.73%
Avg 1-day reaction
+0.29%
Overall, expectations for Cryoport's upcoming earnings are cautious, given the lack of analyst estimates and mixed historical performance.
Bull case
If Cryoport can demonstrate strong revenue growth and effective cost management, it could signal a turnaround and boost investor confidence.
Bear case
Conversely, if the company fails to show improvement in customer acquisition or revenue, it may lead to further declines in stock price.
The print will turn on these.
Q1
What is the revenue growth rate compared to the previous quarter?
This will be a key indicator of whether Cryoport is successfully expanding its business and attracting new customers.
Q2
How have operating expenses changed in relation to revenue?
Understanding the relationship between expenses and revenue will help gauge the company's efficiency and profitability potential.
—
Est. EPS
$-0.50
Est. Rev
$257M
Impl. Move
±8.7%
Why consensus could be wrong
The Street may be underestimating Cryoport's potential for revenue growth due to its innovative logistics solutions, which could capture a larger market share than anticipated.
Supporting evidence
The options market is pricing a 12.57% move, indicating expectations of volatility that may not align with historical performance.
Cryoport's unique positioning in temperature-controlled logistics could lead to higher demand as the biotech sector expands.
Key risk
If revenue growth exceeds expectations significantly, it could challenge the current cautious outlook.
Pre-commit to what would confirm each case.
The core debate this quarter centers around whether Cryoport can effectively grow its revenue while managing costs in a challenging market.
Bull confirmed if
Demonstrating revenue growth of at least 15% quarter-over-quarter would confirm the bull case.
Bear confirmed if
If revenue declines or remains flat, it would validate the bear case.
What the market is pricing for the move.
Implied Move
±12.57%
Historical Avg
±3.0%
The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.
Options are pricing ±12.6% while CYRX has averaged ±3.0% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
28.0%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 12 of 30 (40%)
This setup has occurred 30 times across Health Care in the last 2 years. 12 of 30 faded and 18 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.4%, with a raw directional average of -0.4% (modestly negative historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
95.25%
of float
Insider
3.86%
of float
Holders
247
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
4,218,434 sh · $73.2M
8.33%
6.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Cryoport beats expectations and raises guidance, history suggests the stock could see an average one-day move of around -1.85%, indicating a cautious market response despite positive results.
In line / cautious
If results are in line with expectations, the stock may react modestly, reflecting uncertainty in the market about future growth.
Miss
A miss on earnings could lead to a decline in stock price, with history suggesting an average one-day move of +2.44% when they miss, indicating potential selling pressure.
The lines on the call that would change the story.
Cadian Capital Management, LP
2,920,681 sh · $50.7M
5.77%
-38.8%
Morgan Stanley
2,276,741 sh · $39.5M
4.50%
-50.2%
Vanguard Capital Management LLC
2,151,943 sh · $37.3M
4.25%
1.6%
Millennium Management Llc
1,724,726 sh · $29.9M
3.41%
-41.9%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.